Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2011

01-01-2011 | Commentary

Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase

Authors: N. Stefan, H. Staiger, H.-U. Häring

Published in: Diabetologia | Issue 1/2011

Login to get access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance and type 2 diabetes in humans. Ongoing research aims to clarify the mechanisms involved in this relationship. Studying pathways that are involved in the dissociation between fatty liver and insulin resistance may help to achieve this goal. Among several enzymes that regulate the fate of hepatic lipids, adipose triacylglycerol lipase (ATGL) is of interest. This article briefly summarises novel information about the impact of ATGL in this process.
Literature
1.
2.
Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960CrossRefPubMed
3.
Choi SS, Diehl AM (2008) Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19:295–300CrossRefPubMed
4.
Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267–2277CrossRefPubMed
5.
Fritsche L, Weigert C, Häring HU, Lehmann R (2008) How insulin receptor substrate proteins regulate the metabolic capacity of the liver—implications for health and disease. Curr Med Chem 15:1316–1329CrossRefPubMed
6.
Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616CrossRefPubMed
7.
Fabbrini E, Magkos F, Mohammed BS et al (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106:15430–15435CrossRefPubMed
8.
Tiikkainen M, Bergholm R, Vehkavaara S et al (2003) Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52:701–707CrossRefPubMed
9.
Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N (2010) The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53:882–889CrossRefPubMed
10.
Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57:2762–2767CrossRefPubMed
11.
Ding EL, Song Y, Manson et al (2009) Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361:1152–1163CrossRefPubMed
12.
Stefan N, Schick F, Haring HU (2009) Sex hormone-binding globulin and risk of type 2 diabetes. N Engl J Med 361:2675–2676CrossRefPubMed
13.
Peter A, Kantartzis K, Machann J et al (2010) Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes. doi:10.​2337/​db10-0179 PubMed
14.
15.
Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A (2009) Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res 50:3–21CrossRefPubMed
16.
Haemmerle G, Lass A, Zimmermann R et al (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734–737CrossRefPubMed
17.
Reid BN, Ables GP, Otlivanchik OA et al (2008) Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 283:13087–13099CrossRefPubMed
18.
Brown JM, Betters JL, Lord C et al (2010) CGI-58 knockdown in mice causes hepatic steatosis, but prevents diet-induced obesity and glucose intolerance. J Lipid Res. doi:10.​1194/​jlr.​M010256
Metadata
Title
Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase
Authors
N. Stefan
H. Staiger
H.-U. Häring
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1938-y

Other articles of this Issue 1/2011

Diabetologia 1/2011 Go to the issue

Article

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Article

Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose?

Article

The dicarboxylate carrier plays a role in mitochondrial malate transport and in the regulation of glucose-stimulated insulin secretion from rat pancreatic beta cells

Article

Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse

Article

Immunological and C-peptide studies of patients with diabetes in northern Ethiopia: existence of an unusual subgroup possibly related to malnutrition

Short Communication

An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits